Hrt Financial LP Incyte Corp Transaction History

Hrt Financial LP

$17 Billion
Q2 2024

A detailed history of Hrt Financial LP transactions in Incyte Corp stock. As of the latest transaction made, Hrt Financial LP holds 473,258 shares of INCY stock, worth $31.2 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares

473,258

Previous 183,677 157.66%

Holding current value

$31.2 Million

Previous $10.5 Million 174.16%

% of portfolio

0.17%

Previous 0.07%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$51.18 - $63.75 $14.8 Million - $18.5 Million	289,581 Added 157.66%	473,258 $28.7 Million
Q1 2024 May 13, 2024	BUY	$56.55 - $66.59 $63,336 - $74,580	1,120 Added 0.61%	183,677 $10.5 Million
Q4 2023 Feb 09, 2024	BUY	$52.16 - $64.19 $4.03 Million - $4.96 Million	77,256 Added 73.37%	182,557 $11.5 Million
Q3 2023 Nov 13, 2023	SELL	$57.77 - $65.93 $1.14 Million - $1.3 Million	-19,701 Reduced 15.76%	105,301 $6.08 Million
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $7.62 Million - $9.44 Million	125,002 New	125,002 $7.78 Million
Q4 2022 Feb 10, 2023	BUY	$67.18 - $84.11 $4.85 Million - $6.08 Million	72,231 New	72,231 $5.8 Million
Q2 2022 Aug 12, 2022	BUY	$66.18 - $83.18 $6.11 Million - $7.68 Million	92,347 New	92,347 $7.02 Million
Q1 2022 May 16, 2022	SELL	$66.02 - $79.71 $23 Million - $27.8 Million	-348,268 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $22.1 Million - $25.8 Million	348,268 New	348,268 $25.6 Million
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $4.08 Million - $5 Million	-59,454 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $4.75 Million - $5.2 Million	59,454 New	59,454 $5 Million

Others Institutions Holding INCY

# of Institutions

629

Shares Held

198M

Call Options Held

766K

Put Options Held

476K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $14.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account